Loading...
OTCM
IVRN
Market cap0kUSD
Oct 13, Last price  
0.00USD
Name

H-Cyte Inc

Chart & Performance

D1W1MN
OTCM:IVRN chart
P/E
P/S
0.00
EPS
Div Yield, %
Shrs. gr., 5y
72.67%
Rev. gr., 5y
16.94%
Revenues
453k
-71.86%
0033,0450207,344818,2118,346,8582,150,6721,611,518453,460
Net income
-15m
L+194.38%
-673,333-2,937,032-6,523,077-16,227,484-6,456,477-4,908,644-29,983,091-7,835,170-4,940,456-14,543,494
CFO
-2m
L-60.21%
-573,736-2,759,875-5,981,944-5,427,468-5,590,467-2,341,164-12,291,275-7,257,743-4,809,810-1,913,738

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
IPO date
Dec 19, 2014
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT